Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: Case series and literature review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: Case series and literature review
Authors
Keywords
JAK2, Myelofibrosis, Ruxolitinib, Tuberculosis
Journal
Hematology/ Oncology and Stem Cell Therapy
Volume 14, Issue 3, Pages 252-256
Publisher
Elsevier BV
Online
2020-03-16
DOI
10.1016/j.hemonc.2020.02.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management
- (2016) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
- (2015) D Pietra et al. LEUKEMIA
- Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge
- (2014) Francesca Palandri et al. ANNALS OF HEMATOLOGY
- How I treat myelofibrosis
- (2014) F. Cervantes BLOOD
- Disseminated tuberculosis associated with ruxolitinib
- (2014) R K Hopman et al. LEUKEMIA
- Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis
- (2014) Yen-Hao Chen et al. LEUKEMIA & LYMPHOMA
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
- (2013) A. Heine et al. BLOOD
- An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
- (2013) Nicholas G. Wysham et al. CHEST
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
- (2013) G Caocci et al. LEUKEMIA
- Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- (2013) Rowan Wathes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib
- (2013) Roger A. Goldberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started